Over the past year, Inovio has reduced its workforce by 16 percent to preserve cash while waiting for FDA ruling on its new drug application.
Over the past year, Plymouth Meeting-based Inovio Pharmaceuticals has reduced its workforce by 16 percent to preserve cash as it waits for the Food and Drug Administration ruling on its new drug application, writes John George for the Philadelphia Business Journal.
The FDA will determine by October 30 whether INO-3107, an experimental therapy from Inovio Pharmaceuticals, can be approved to treat recurrent respiratory papillomatosis, or RRP, in adults…